European Society of Human Reproduction and Embryology. The guideline development group on premature ovarian insufficiency. Premature ovarian insufficiency (POI). European Society of Human Reproduction and Embryology; 2024. Available from: www.eshre.eu/guidelines
FedericiS, RossettiR, MoleriS, et al.Primary ovarian insufficiency: Update on clinical and genetic findings. Front Endocrinol (Lausanne), 2024; 15:1464803; doi: 10.3389/fendo.2024.1464803
4.
WeltCK. Primary ovarian insufficiency: A more accurate term for premature ovarian failure. Clin Endocrinol (Oxf), 2008; 68(4):499–509; doi: 10.1111/j.1365-2265.2007.03073.x
5.
PanayN, AndersonRA, NappiRE, et al.Premature ovarian insufficiency: An international menopause society white paper. Climacteric, 2020; 23(5):426–446; doi: 10.1080/13697137.2020.1804547
6.
Ovarian StimulationT, BoschE, BroerS, et al.ESHRE guideline: Ovarian stimulation for IVF/ICSI(†). Hum Reprod Open, 2020; 2020(2):hoaa009; doi: 10.1093/hropen/hoaa009
7.
HamodaH, SharmaA. Premature ovarian insufficiency, early menopause, and induced menopause. Best Pract Res Clin Endocrinol Metab, 2024; 38(1):101823; doi: 10.1016/j.beem.2023.101823
8.
GoodmanMP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health (Larchmt), 2012; 21(2):161–169; doi: 10.1089/jwh.2011.2839
9.
GoldstuckND. The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: Essential differences and perspectives. Eur J Contracept Reprod Health Care, 2023; 28(3):177–183; doi: 10.1080/13625187.2023.2197091
10.
CoxP, PanayN. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause. Climacteric, 2023; 26(4):367–372; doi: 10.1080/13697137.2023.2210283
11.
Crean-TateKK, FaubionSS, PedersonHJ, et al.Management of genitourinary syndrome of menopause in female cancer patients: A focus on vaginal hormonal therapy. Am J Obstet Gynecol, 2020; 222(2):103–113; doi: 10.1016/j.ajog.2019.08.043
